NewStem filed a pre-submission to the FDA for a De Novo Request and an in vitro diagnostic device (IVDD) filing for Europe, the Middle East and Africa in April 2022, representing progress toward regulatory validation. The company graduated from Illumina's Accelerator program in March 2022, indicating industry validation. Additionally, NovelStem holds a 50/50 joint venture stake in Netco Partners, which owns rights to exploit the Tom Clancy's Net Force franchise across film, TV, streaming, and gaming, creating a dual-asset portfolio.
Cyborg Score Rationale
NovelStem is a pre-revenue development-stage company with regulatory milestones but limited commercial traction as of June 2026. The stem cell diagnostic technology shows technical promise but remains early-stage, with FDA approval still pending. The entertainment IP holding provides diversification but lacks clear monetization strategy.
Top Insights
Development-stage biotech holding company with 30%+ ownership stake in Israel-based NewStem Ltd., a bioinformatics platform for cancer drug resistance prediction
FDA pre-submission filed in April 2022 for diagnostic device; regulatory pathway unclear as of June 2026 with no clearance announced to date
Dual asset strategy includes 50/50 joint venture with C.P. Group in Netco Partners (Tom Clancy Net Force IP) with arbitration-confirmed licensing rights as of July 2023
NewStem selected for Illumina's Accelerator program in September 2021, indicating third-party validation but limited evidence of commercial partnerships or revenue generation
Named Competitors
Guardant Health — Liquid biopsy and precision oncology diagnostics
Foundation Medicine — Comprehensive genomic profiling for cancer treatment
Tempus AI — AI-driven oncology diagnostics and treatment planning
Recent Developments
(July 2023) Arbitration confirmed NovelStem's rights through Netco Partners to license Tom Clancy's Net Force franchise for film, TV, streaming, gaming, and merchandising
(April 2022) NewStem filed FDA pre-submission and EMA in vitro diagnostic device filing for NewStem Software Diagnostic Device
(March 2022) NewStem graduated from Illumina's Accelerator 3rd funding cycle
Open the full interactive NovelStem International Corp. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.